Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients With Moderate COVID-19
Status:
Recruiting
Trial end date:
2023-07-20
Target enrollment:
Participant gender:
Summary
This is a double-blind, multicentre, multinational study to evaluate the safety and collect
preliminary efficacy data of Codivir drug product in 130 hospitalized adults with moderate
COVID-19 symptoms. COVID-19 symptoms (fever, cough, myalgia and changes in smell or taste)
onset must be within 7 days prior enrolment. Treatment will begin in the hospital,
participants will be discharged according to medical decision and continue the treatment
until to Day 7 at home and followed up to day 28.